AZD0486

Phase 1Small molecule

AstraZeneca

AZD0486 is one of 16 small molecule programs targeting Chronic Lymphocytic Leukaemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic LeukaemiaRecruiting

B-Cell Acute Lymphoblastic Leukemia (b-ALL)Recruiting

B-Cell Non Hodgkin LymphomaActive, not recruiting

Chronic Lymphocytic LeukaemiaPreclinical

Recruiting

B-Cell Acute Lymphoblastic Leukemia (b-ALL)Preclinical

Recruiting

B-Cell Non Hodgkin LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

18 competitors in B-Cell Non Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

5 2

Adriamycin

Pfizer

Phase 2

1 3

Oncovin

Eli Lilly

Phase 2

1 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

4 5

Rayos

RRoxane Laboratories

Phase 2

4 6

Surovatamig

AstraZeneca

Phase 2

2 7

LUNSUMIO

Roche

Phase 1

1 8

Polivy

Roche

Phase 1

1 9

COLUMVI

Roche

Phase 1

1 10

Gazyva

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Active, not recruiting

B-Cell Non Hodgkin Lymphoma

NCT04594642

Q3 2028

PreclinicalRecruiting

B-Cell Acute Lymphoblastic Leukemia (b-ALL)

NCT06137118

Q2 2030

PreclinicalRecruiting

Chronic Lymphocytic Leukaemia

NCT06564038

Q3 2033

Phase 3Recruiting

Large B-Cell Lymphoma

NCT07215585

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukaemia1 trial

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06564038·408 enrolled

B-cell Acute Lymphoblastic Leukemia (B-ALL)1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT06137118·255 enrolled

Large B-cell Lymphoma1 trial

A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07215585·420 enrolled

B-cell Non Hodgkin Lymphoma1 trial

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04594642·226 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AZD0486. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD0486 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD0486. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AstraZeneca

AZD0486

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2028

Q2 2030

Q3 2033

Trials by Indication[1]

Chronic Lymphocytic Leukaemia1 trial

B-cell Acute Lymphoblastic Leukemia (B-ALL)1 trial

Large B-cell Lymphoma1 trial

B-cell Non Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News